The speaker was short, anticipating a clinical trial failure. After the data release, it was described as 'incrementally bad' and not good enough for the stock to go up, as the drug's advantage over the control arm narrowed significantly.

Speaker is explicitly bearish ahead of a binary data release, stating 'I don't think Cardiff's going to make it' and implying a short position with a 90% chance of failure.